Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization

Vaccine

Volumn 32, Issue 15, 2014, Pages 1727-1735

  Watanabe, Kenta ^a   Matsubara, Akihiro ^a,b   Kawano, Mitsuo ^b   Mizuno, Satoru ^c,d   Okamura, Tomotaka ^a   Tsujimura, Yusuke ^a   Inada, Hiroyasu ^e   Nosaka, Tetsuya ^b   Matsuo, Kazuhiro ^c   Yasutomi, Yasuhiro ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Kiyose   (Japan)

^d RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^e SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Ag85B; Human parainfluenza virus; Mucosal immunity; Tuberculosis

Indexed keywords

BCG VACCINE; RECOMBINANT VACCINE; RETINOIC ACID INDUCIBLE PROTEIN I; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; GENE ELIMINATION; GENETIC PARAMETERS; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARAINFLUENZA TYPE 2 VIRUS; PARAMYXOVIRUS; PRIORITY JOURNAL; SPLEEN;

AG85B; HUMAN PARAINFLUENZA VIRUS; MUCOSAL IMMUNITY; TUBERCULOSIS;

ACYLTRANSFERASES; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PARAINFLUENZA VIRUS 2, HUMAN; RECOMBINANT PROTEINS; REVERSE GENETICS; TUBERCULOSIS VACCINES; VACCINES, SYNTHETIC;

EID: 84895899531     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.108     Document Type: Article

References (46)

1. Small J.C., Ertl H.C. Viruses - from pathogens to vaccine carriers. Curr Opin Virol 2011, 1(October (4)):241-245.
2. Halle S., Dujardin H.C., Bakocevic N., Fleige H., Danzer H., Willenzon S., et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 2009, 206(November (12)):2593-2601.
3. Okano S., Yonemitsu Y., Shirabe K., Kakeji Y., Maehara Y., Harada M., et al. Provision of continuous maturation signaling to dendritic cells by RIG-I-stimulating cytosolic RNA synthesis of Sendai virus. J Immunol 2011, 186(February (3)):1828-1839.
4. Moriya C., Horiba S., Kurihara K., Kamada T., Takahara Y., Inoue M., et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies. Vaccine 2011, 29(November (47)):8557-8563.
5. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996, 348(July (9019)):17-24.
6. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366(October (9493)):1290-1295.
7. Zinselmeyer B.H., Dempster J., Gurney A.M., Wokosin D., Miller M., Ho H., et al. In situ characterization of CD4+ T cell behavior in mucosal and systemic lymphoid tissues during the induction of oral priming and tolerance. J Exp Med 2005, 201(June (11)):1815-1823.
8. Dwivedy A., Aich P. Importance of innate mucosal immunity and the promises it holds. Int J Gen Med 2011, 4:299-311.
9. Kiyono H., Kweon M.N., Hiroi T., Takahashi I. The mucosal immune system: from specialized immune defense to inflammation and allergy. Acta Odontol Scand 2001, 59(June (3)):145-153.
10. Kawano M., Kaito M., Kozuka Y., Komada H., Noda N., Nanba K., et al. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 2001, 284(May (1)):99-112.
11. Takamura S., Matsuo K., Takebe Y., Yasutomi Y. Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 2005, 175(August (4)):2541-2547.
12. Sugawara I., Mizuno S., Yamada H., Matsumoto M., Akira S. Disruption of nuclear factor-interleukin-6, a transcription factor, results in severe mycobacterial infection. Am J Pathol 2001, 158(February (2)):361-366.
13. Sugawara I., Yamada H., Kazumi Y., Doi N., Otomo K., Aoki T., et al. Induction of granulomas in interferon-gamma gene-disrupted mice by avirulent but not by virulent strains of Mycobacterium tuberculosis. J Med Microbiol 1998, 47(October (10)):871-877.
14. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17(October (10)):1261-1268.
15. Shafiani S., Tucker-Heard G., Kariyone A., Takatsu K., Urdahl K.B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010, 207(July (7)):1409-1420.
16. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(January (1)):62-73.
17. Clark K.R., Johnson P.R. Gene delivery of vaccines for infectious disease. Curr Opin Mol Ther 2001, 3(August (4)):375-384.
18. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005, 174(June (11)):7179-7185.
19. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194(December (12)):1638-1649.
20. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46(June (11)):1769-1781.
21. Hara H., Hironaka T., Inoue M., Iida A., Shu T., Hasegawa M., et al. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. Hum Vaccin 2011, 7(June (6)):639-645.
22. McShane H., Brookes R., Gilbert S.C., Hill A.V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001, 69(February (2)):681-686.
23. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75(August (8)):4105-4115.
24. Munier C.M., Andersen C.R., Kelleher A.D. HIV vaccines: progress to date. Drugs 2011, 71(March (4)):387-414.
25. Cheng C., Wang L., Gall J.G., Nason M., Schwartz R.M., McElrath M.J., et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS ONE 2012, 7(4):e33969.
26. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181(June (12)):1407-1417.
27. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10(November (11)):1240-1244.
28. Rahman S., Magalhaes I., Rahman J., Ahmed R.K., Sizemore D.R., Scanga C.A., et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8(+) cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol Med 2012, 18:647-658.
29. Pathan A.A., Minassian A.M., Sander C.R., Rowland R., Porter D.W., Poulton I.D., et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 2012, 30(August (38)):5616-5624.
30. Tokusumi T., Iida A., Hirata T., Kato A., Nagai Y., Hasegawa M. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res 2002, 86(June (1-2)):33-38.
31. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., Mizuguchi H. Innate immune response induced by gene delivery vectors. Int J Pharm 2008, 354(April (1-2)):9-15.
32. Chen D., Murphy B., Sung R., Bromberg J.S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther 2003, 10(June (11)):991-998.
33. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(November (10)):6357-6365.
34. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006, 177(November (9)):6353-6360.
35. Ballester M., Nembrini C., Dhar N., de Titta A., de Piano C., Pasquier M., et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29(September (40)):6959-6966.
36. Wolf A.J., Desvignes L., Linas B., Banaiee N., Tamura T., Takatsu K., et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008, 205(January (1)):105-115.
37. Moreno-Mendieta S.A., Rocha-Zavaleta L., Rodriguez-Sanoja R. Adjuvants in tuberculosis vaccine development. FEMS Immunol Med Microbiol 2010, 58(February (1)):75-84.
38. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012, 122(January (1)):303-314.
39. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17(February (2)):189-194.
40. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2(October (53)):53ra74.
41. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccine 2009, 5(July (7)):475-482.
42. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(October (6857)):732-738.
43. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441(May (7089)):101-105.
44. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 1999, 73(January (1)):251-259.
45. Yasui F., Kai C., Kitabatake M., Inoue S., Yoneda M., Yokochi S., et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008, 181(November (9)):6337-6348.
46. Falkner F.G., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1988, 62(June (6)):1849-1854.